Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where George M. Carlone is active.

Publication


Featured researches published by George M. Carlone.


Journal of Clinical Microbiology | 2007

Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA.

Maria da Gloria Carvalho; Maria L. Tondella; Karen A. McCaustland; Luciana Weidlich; Lesley McGee; Leonard W. Mayer; Arnold G. Steigerwalt; Melissa Whaley; Richard R. Facklam; Barry S. Fields; George M. Carlone; Edwin W. Ades; Ron Dagan; Jacquelyn S. Sampson

ABSTRACT The accurate diagnosis of pneumococcal disease has frequently been hampered not only by the difficulties in obtaining isolates of the organism from patient specimens but also by the misidentification of pneumococcus-like viridans group streptococci (P-LVS) as Streptococcus pneumoniae. This is especially critical when the specimen comes from the respiratory tract. In this study, three novel real-time PCR assays designed for the detection of specific sequence regions of the lytA, ply, and psaA genes were developed (lytA-CDC, ply-CDC, and psaA, respectively). These assays showed high sensitivity (<10 copies for lytA-CDC and ply-CDC and an approximately twofold less sensitivity for psaA). Two additional real-time PCR assays for lytA and ply described previously for pneumococcal DNA detection were also evaluated. A panel of isolates consisting of 67 S. pneumoniae isolates (44 different serotypes and 3 nonencapsulated S. pneumoniae isolates from conjunctivitis outbreaks) and 104 nonpneumococcal isolates was used. The 67 S. pneumoniae isolates were reactive in all five assays. The new real-time detection assays targeting the lytA and psaA genes were the most specific for the detection of isolates confirmed to be S. pneumoniae, with lytA-CDC showing the greatest specificity. Both ply PCRs were positive for all isolates of S. pseudopneumoniae, along with 13 other isolates of other P-LVS isolates confirmed to be non-S. pneumoniae by DNA-DNA reassociation. Thus, the use of the ply gene for the detection of pneumococci can lead to false-positive reactions in the presence of P-LVS. The five assays were applied to 15 culture-positive cerebrospinal fluid specimens with 100% sensitivity; and serum and ear fluid specimens were also evaluated. Both the lytA-CDC and psaA assays, particularly the lytA-CDC assay, have improved specificities compared with those of currently available assays and should therefore be considered the assays of choice for the detection of pneumococcal DNA, particularly when upper respiratory P-LVS might be present in the clinical specimen.


Vaccine | 2003

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

Luis Jódar; Jay C. Butler; George M. Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith P. Klugman; Brian D. Plikaytis; George R. Siber; Robert Kohberger; Ih Chang; Thomas Cherian

The World Health Organization (WHO) is undertaking a series of consultations on serological criteria for the evaluation and licensure of new formulations/combinations or different vaccination schedules of pneumococcal conjugate vaccines. The lack of a definitive serological correlate of protection and the multiplicity of antigens involved, especially since the clinical efficacy of most of the individual serotypes represented in the only licensed vaccine has not been established, are hindering the formulation of criteria for licensure of new formulations or combinations of the vaccine. This report analyses the various options with their relative merits and drawbacks and provides preliminary recommendations as guidance to regulatory agencies in evaluating these vaccines for the purposes of licensure. More detailed recommendations for production and control of pneumococcal conjugate vaccines, including criteria for evaluation for licensure, are currently being drafted.


Infection and Immunity | 2000

Intranasal Immunization of Mice with a Mixture of the Pneumococcal Proteins PsaA and PspA Is Highly Protective against Nasopharyngeal Carriage of Streptococcus pneumoniae

David E. Briles; Eddie Ades; James C. Paton; Jacquelyn S. Sampson; George M. Carlone; Robert C. Huebner; Anni Virolainen; Edwin Swiatlo; Susan K. Hollingshead

ABSTRACT Acquisition of pneumococci is generally from carriers rather than from infected individuals. Therefore, to induce herd immunity againstStreptococcus pneumoniae it will be necessary to elicit protection against carriage. Capsular polysaccharide-protein conjugates, PspA, and PsaA are known to elicit some protection against nasopharyngeal carriage of pneumococci but do not always completely eliminate carriage. In this study, we observed that PsaA elicited better protection than did PspA against carriage. Pneumolysin elicited no protection against carriage. Immunization with a mixture of PsaA and PspA elicited the best protection against carriage. These results indicate that PspA and PsaA may be useful for the elicitation of herd immunity in humans. As PspA and pneumolysin are known to elicit immunity to bacteremia and pneumonia, their inclusion in a mucosal vaccine may enable such a vaccine to prevent invasive disease as well as carriage.


Clinical and Vaccine Immunology | 2003

Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal Polysaccharides

Catherine M. Wernette; Carl E. Frasch; Dace V. Madore; George M. Carlone; David Goldblatt; Brian D. Plikaytis; William H. Benjamin; Sally A. Quataert; Steve Hildreth; Daniel J. Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H. Nahm

Streptococcus pneumoniae is a major human pathogen causing pneumonia, sepsis, meningitis, and otitis media ([12][1]). It causes infections most often in young children ([12][1]) and elderly adults ([1][2]) because their immune systems are either unprepared or unable to respond effectively to


Clinical Infectious Diseases | 1999

Reduction in Functional Antibody Activity Against Streptococcus pneumoniae in Vaccinated Elderly Individuals Highly Correlates with Decreased IgG Antibody Avidity

Sandra Romero-Steiner; Daniel M. Musher; Marty S. Cetron; Lorna B. Pais; Jean E. Groover; Anthony E. Fiore; Brian D. Plikaytis; George M. Carlone

The pneumococcal polysaccharide vaccine is recommended as a means of preventing invasive disease in the elderly. We compared responses to the 23-valent polysaccharide vaccine in 46 previously unvaccinated, healthy, institutionalized elderly persons (mean age, 85.5 years) with those in 12 healthy younger adults (mean age, 37 years) by measuring prevaccination and postvaccination serum IgG antibody concentrations (by ELISA), functional antibody activity (by opsonophagocytosis), IgG antibody avidity, and passive protection in mice. Postvaccination IgG antibody concentrations for two serotypes (6B and 19F) of the five studied (4, 6B, 14, 19F, and 23F) were significantly lower in elderly than in younger adults; however, opsonophagocytic activity was significantly reduced for all serotypes in the elderly. Sera with reduced opsonophagocytic activity (titer, <64) correlated with low IgG antibody avidity and protected mice poorly against pneumococcal challenge. In elderly persons receiving polysaccharide vaccination, there was a significant reduction in the functionality of postvaccination antibodies, and this appeared to increase with advanced age.


The Journal of Infectious Diseases | 1998

Immunogenicity of Two Efficacious Outer Membrane Protein-Based Serogroup B Meningococcal Vaccines among Young Adults in Iceland

Bradley A. Perkins; K. Jonsdottir; H. Briem; E. Griffiths; Brian D. Plikaytis; E. A. Hoiby; Einar Rosenqvist; J. Holst; Hanne Nøkleby; F. Sotolongo; G. Sierra; H. C. Campa; George M. Carlone; D. Williams; Janet K. Dykes; D. Kapczynski; E. Tikhomirov; J. D. Wenger; C. V. Broome

Serum bactericidal activity (SBA) and ELISA antibody levels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled trial involving 408 15- to 20-year-olds. Subjects were given two doses at a 6-week interval of a serogroup B or control vaccine. Response was defined as > or = 4-fold rise in antibody level. After two doses of the Finlay Institute (Havana) vaccine at 12 months, the proportions of SBA and ELISA responders were not different from those of the control group (15% and 17% [vaccine] vs. 13% and 9% [control], P > .05). After two doses of the National Institute of Public Health (Oslo) vaccine, there were more SBA and ELISA responders than in the control group (47% and 34% [vaccine] vs. 10% and 1% [control]) or the Finlay Institute vaccine group (P < .05 for both). SBA and ELISA may be insensitive correlates for protective efficacy for some outer membrane protein-based serogroup B meningococcal vaccines.


The New England Journal of Medicine | 2010

Advances in the Development of Vaccines against Neisseria meningitidis

Lionel Tan; George M. Carlone; Ray Borrow

Developments during the past decade have renewed hopes for solving this seemingly intractable problem. Knowledge of the meningococcal genome has led to the identification of novel antigens that have been incorporated into the NMB vaccines now being studied in clinical trials. However, it remains unclear whether these vaccines will provide sufficient immunogenicity in infants as well as wide-ranging coverage. This review highlights the evolution of meningococcal vaccines in general and discusses strategies being used to overcome the barriers to developing vaccines against NMB. Epidemiology of N. meningitidis Infection Meningococcal disease is a global health problem. The World Health Organization estimates that there are 1.2 million cases of invasive meningococcal disease and 135,000 related deaths annually. 3 Although the disease occurs sporadically in industrialized countries, with an incidence of 0.35 cases per 100,000 population in the United States and of 1.01 per 100,000 in Europe (ranging from 0.25 to 4.4 per 100,000 in Italy and Malta, respectively), 4 the major disease burden is in the nonindustrialized countries. A recent epidemic in Nigeria resulted in 4164 cases and 171 deaths in 1 week alone. 5 The meningococcus is pathogenic only in humans. It colonizes the nasopharynx asymptomatically in up to 40% of the adult population but occasionally causes invasive disease. When the infection is classified according to the polysaccharide capsule surrounding the bacterium, only six capsular groups (A, B, C, W-135, X, and Y) are associated with invasive disease. 6 The epidemiology of disease caused by these groups varies: group A is responsible for large epidemics in Africa, in which the incidence approaches 1000 cases per 100,000 population (and may involve environmental factors), whereas groups B and C cause disease predominantly in industrialized and newly industrialized countries. 2,6 Recently, groups W-135 and X (predominantly in Africa) and group Y (in the United States and other countries) have emerged as important disease-causing isolates.


Emerging Infectious Diseases | 2002

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Conrad P. Quinn; Vera A. Semenova; Cheryl M. Elie; Sandra Romero-Steiner; Carolyn M. Greene; Han Li; Karen Stamey; Evelene Steward-Clark; Daniel S. Schmidt; Elizabeth A. Mothershed; Janet M. Pruckler; Stephanie B. Schwartz; Robert F. Benson; Leta O. Helsel; Patricia Holder; Scott E. Johnson; Molly E. Kellum; Trudy O. Messmer; W. Lanier Thacker; Lilah Besser; Brian D. Plikaytis; Thomas H. Taylor; Alison E. Freeman; Kelly J. Wallace; Peter M. Dull; Jim Sejvar; Erica Bruce; Rosa Moreno; Anne Schuchat; Jairam R. Lingappa

The bioterrorism-associated human anthrax epidemic in the fall of 2001 highlighted the need for a sensitive, reproducible, and specific laboratory test for the confirmatory diagnosis of human anthrax. The Centers for Disease Control and Prevention developed, optimized, and rapidly qualified an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) antibodies to Bacillus anthracis protective antigen (PA) in human serum. The qualified ELISA had a minimum detection limit of 0.06 µg/mL, a reliable lower limit of detection of 0.09 µg/mL, and a lower limit of quantification in undiluted serum specimens of 3.0 µg/mL anti-PA IgG. The diagnostic sensitivity of the assay was 97.8%, and the diagnostic specificity was 94.2%. A competitive inhibition anti-PA IgG ELISA was also developed to enhance diagnostic specificity to 100%. The anti-PA ELISAs proved valuable for the confirmation of cases of cutaneous and inhalational anthrax and evaluation of patients in whom the diagnosis of anthrax was being considered.


Clinical and Vaccine Immunology | 2006

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

Sandra Romero-Steiner; Carl E. Frasch; George M. Carlone; Roland A. Fleck; David Goldblatt; Moon H. Nahm

Since 2000, when a pneumococcal conjugate vaccine (Prevnar) was introduced, pneumococcal infections in the United States among children have been dramatically reduced. The conjugate vaccine elicits antibodies to pneumococcal capsular polysaccharide, and these antibodies protect the host by


The Journal of Infectious Diseases | 2000

Natural Development of Antibodies to Pneumococcal Surface Protein A, Pneumococcal Surface Adhesin A, and Pneumolysin in Relation to Pneumococcal Carriage and Acute Otitis Media

Satu Rapola; Virva Jäntti; Raili Haikala; Ritva Syrjänen; George M. Carlone; Jacquelyn S. Sampson; David E. Briles; James C. Paton; Aino K. Takala; Terhi Kilpi; Helena Käyhty

Pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), and pneumolysin (Ply) are common to virtually all Streptococcus pneumoniae isolates. They are immunogenic and protective against pneumococcal challenge in animals and are the major candidates for a protein-based pneumococcal vaccine for humans. However, little is known of the natural development of antibodies to these proteins in humans. The objective of this study was to evaluate the natural development of antibodies to PspA, PsaA, and Ply in relation to pneumococcal infection and carriage in young children. Serum antibodies to these proteins were measured by EIA in children at ages 6, 12, 18, and 24 months and in their mothers. All age groups were capable of producing antibodies to the 3 proteins. The antibody concentrations increased with age and were strongly associated with pneumococcal exposure, whether by carriage or infection (acute otitis media).

Collaboration


Dive into the George M. Carlone's collaboration.

Top Co-Authors

Avatar

Jacquelyn S. Sampson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Edwin W. Ades

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sandra Romero-Steiner

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Brian D. Plikaytis

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Gowrisankar Rajam

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Scott E. Johnson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Cheryl M. Elie

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Patricia Holder

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Joseph E. Martinez

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge